Patents by Inventor Ying-hui Fu
Ying-hui Fu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160258022Abstract: The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing acardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.Type: ApplicationFiled: March 8, 2016Publication date: September 8, 2016Applicant: University of Utah Research FoundationInventors: Louis J. Ptacek, Ying-Hui Fu
-
Publication number: 20140342926Abstract: The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.Type: ApplicationFiled: February 11, 2014Publication date: November 20, 2014Applicant: University of Utah Research FoundationInventors: Louis J. Ptacek, Ying-Hui Fu
-
Publication number: 20080220430Abstract: The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.Type: ApplicationFiled: October 30, 2007Publication date: September 11, 2008Inventors: Louis Ptacek, Ying-Hui Fu
-
Patent number: 7306911Abstract: The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.Type: GrantFiled: April 22, 2002Date of Patent: December 11, 2007Assignee: University of Utah Research FoundationInventors: Louis Ptacek, Ying-Hui Fu
-
Patent number: 7285641Abstract: The present invention discloses antibodies that specifically bind to a WRN gene product or a portion thereof.Type: GrantFiled: February 25, 2003Date of Patent: October 23, 2007Inventors: Ying-Hui Fu, Chang-En Yu, Junko Oshima, John T Mulligan, Gerard D Schellenberg
-
Publication number: 20050175995Abstract: The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.Type: ApplicationFiled: April 22, 2002Publication date: August 11, 2005Inventors: Louis Ptacek, Ying-Hui Fu
-
Publication number: 20050015822Abstract: The present invention relates to a novel gene which is associated with audiogenic seizures in mice. The gene is known as the Monogenic Audiogenic Seizure-susceptible gene or mass1. The product of the mass1 gene is designated MASS1. Nucleic acid molecules that encode for MASS1 have been identified and purified. The sequence of murine mass1 can be found at SEQ ID NO: 1, and the sequence of human mass1 can be found at SEQ ID NO: 3. Mammalian genes encoding a MASS1 protein are also provided. The invention also provides recombinant vectors comprising nucleic acid molecules that code for a MASS1 protein. These vectors can be plasmids. In certain embodiments, the vectors are prokaryotic or eukaryotic expression vectors. The nucleic acid coding for MASS1 can be linked to a heterologous promoter. The invention also relates to transgenic animals in which one or both alleles of the endogenous mass1 gene is mutated.Type: ApplicationFiled: August 4, 2004Publication date: January 20, 2005Inventors: Louis Ptacek, H. White, Ying-Hui Fu, Shana Skradski
-
Patent number: 6794187Abstract: The present invention relates to a novel gene which is associated with audiogenic seizures in mice. The gene is known as the Monogenic Audiogenic Seizure-susceptible gene or mass1. The product of the mass1 gene is designated MASS1. Nucleic acid molecules that encode for MASS1 have been identified and purified. The sequence of murine mass1 can be found at SEQ ID NO: 1, and the sequence of human mass1 can be found at SEQ ID NO: 3. Mammalian genes encoding a MASS1 protein are also provided. The invention also provides recombinant vectors comprising nucleic acid molecules that code for a MASS1 protein. These vectors can be plasmids. In certain embodiments, the vectors are prokaryotic or eukaryotic expression vectors. The nucleic acid coding for MASS1 can be linked to a heterologous promoter. The invention also relates to transgenic animals in which one or both alleles of the endogenous mass1 gene is mutated.Type: GrantFiled: September 3, 2002Date of Patent: September 21, 2004Assignee: University of Utah Research FoundationInventors: Louis J. Ptacek, H. Steve White, Ying-Hui Fu, Shana Skradski
-
Publication number: 20040146873Abstract: The present invention includes the disclosure of the hPER2 gene and a mutant of the hPER2 gene that participates in the human circadian biological clock. The product of the mutant hPER2 gene found in some familial advanced sleep phase syndrome patients is hypophosphorylated by casein kinase epsilon due to the serine-to-glycine mutation caused by the point mutation of the genomic sequence. Specifically, this serine-to-glycine mutation affects the casein kinase epsilon binding region of the hPER2 protein, thus blocking the phosphorylation cascade ordinarily caused by the binding of casein kinase epsilon to hPER2.Type: ApplicationFiled: June 24, 2003Publication date: July 29, 2004Inventors: Louis Ptacek, Ying-Hui Fu, Christopher Jones, David Virshup
-
Publication number: 20040006779Abstract: The present invention discloses nucleic acid molecules encoding WRN gene products, expression vectors and host cells suitable for expressing such products.Type: ApplicationFiled: February 25, 2003Publication date: January 8, 2004Inventors: Ying-Hui Fu, Chang-En Yu, Junko Oshima, John T. Mulligan, Gerard D. Schellenberg
-
Publication number: 20030208782Abstract: The present invention relates to a novel gene which is associated with audiogenic seizures in mice. The gene is known as the Monogenic Audiogenic Seizure-susceptible gene or mass1. The product of the mass1 gene is designated MASS1. Nucleic acid molecules that encode for MASS1 have been identified and purified. The sequence of murine mass1 can be found at SEQ ID NO: 1, and the sequence of human mass1 can be found at SEQ ID NO: 3. Mammalian genes encoding a MASS1 protein are also provided. The invention also provides recombinant vectors comprising nucleic acid molecules that code for a MASS1 protein. These vectors can be plasmids. In certain embodiments, the vectors are prokaryotic or eukaryotic expression vectors. The nucleic acid coding for MASS1 can be linked to a heterologous promoter. The invention also relates to transgenic animals in which one or both alleles of the endogenous mass1 gene is mutated.Type: ApplicationFiled: September 3, 2002Publication date: November 6, 2003Inventors: Louis J. Ptacek, H. Steve White, Ying-Hui Fu, Shana Skradski
-
Patent number: 6583112Abstract: The present invention discloses nucleic acid molecules encoding WRN gene products, expression vectors and host cells suitable for expressing such products.Type: GrantFiled: July 17, 2000Date of Patent: June 24, 2003Inventors: Ying-Hui Fu, Chang-En Yu, Junko Oshima, John T. Mulligan, Gerard D. Schellenberg
-
Patent number: 6180337Abstract: A sequence of the FMR-1 gene is disclosed. This sequence and related probes, cosmids and unique repeats are used to detect X-linked diseases and especially the fragile X syndrome. Also, methods using methylation-sensitive restriction endonuclease and PCR primer probes were used to detect X-linked disease.Type: GrantFiled: August 29, 1991Date of Patent: January 30, 2001Assignee: Baylor College of MedicineInventors: C. Thomas Caskey, David L. Nelson, Maura Pieretti, Stephen T. Warren, Ben A. Oostra, Ying-hui Fu
-
Patent number: 6090620Abstract: The present invention discloses nucleic acid molecules encoding WRN gene products, expresion vectors, viral vectors, and host cells suitable for expressing such products.Type: GrantFiled: December 27, 1996Date of Patent: July 18, 2000Assignee: University of WashingtonInventors: Ying-Hui Fu, Chang-En Yu, Junko Oshima, John T. Mulligan, Gerard D. Schellenberg
-
Patent number: 5552282Abstract: The present invention includes a DNA clone from the myotonic muscular dystrophy gene, a cosmid probe to the myotonic dystrophy site, as well as methods of detecting myotonic muscular dystrophy using RFLP. The method involves the steps of digesting DNA from an individual to be tested with a restriction endonuclease and detecting the restriction fragment length polymorphism with hybridization to probes within the myotonic muscular locus and southern blot analysis. Alternatively, the myotonic muscular dystrophy gene can be measured by determining the amount of mRNA or measuring the amount of protein with an antibody. Further, the myotonic muscular dystrophy gene defect can be detected using either fluorescence in situ hybridization or pulsed field gel electrophoresis using the probes described herein.Type: GrantFiled: June 6, 1993Date of Patent: September 3, 1996Assignee: Baylor College of MedicineInventors: C. Thomas Caskey, Ying-Hui Fu, David L. Friedman, Antonio Pizzuti, Raymond G. Fenwick